Dr. Jay Siegel, M.D.,
ROCKVILLE, MD, Nov. 15, 2017 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced the appointment of Jay Siegel, M.D., former Chief Biotechnology Officer and Head of Scientific Strategy and Policy at Johnson & Johnson, to its Board of Directors.
Dr. Siegel recently retired from Johnson & Johnson, which he joined in 2003 after a distinguished career at the U.S. Food and Drug Administration (FDA). In his former position with Johnson & Johnson, Dr. Siegel was engaged both in R&D leadership across Johnson & Johnson sectors and in policy development and advocacy regarding scientific and regulatory issues at the national and international levels. Dr. Siegel joined Johnson & Johnson in 2003 as President of Centocor Research & Development, Inc., and subsequently served as Group President of R&D for Biotechnology, Immunology and Oncology; as Head of Global Regulatory Affairs and Head of the Biotechnology Center of Excellence at Janssen. Before joining Johnson & Johnson, Dr. Siegel spent 20 years at the FDA Center for Biologics Evaluation & Research in positions of increasing responsibility, including directing the office responsible for review and approval of therapeutic biologics.
Dr. Siegel received a B.S. in Biology from the California Institute of Technology and an M.D. from Stanford University. He trained in internal medicine at the University of California, San Francisco, and in Infectious Disease and Immunology at Stanford University.
“Dr. Siegel is a highly respected leader in our industry and his experience in both R&D strategy and regulatory policy will prove invaluable to our team,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We welcome his deep expertise and contributions as we continue to advance our potential treatment options for patients with cancer, autoimmune disorders and infectious diseases.”
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com.